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Background: Brain thrombin activity is increased following acute ischemic stroke and may 
play a pathogenic role through the protease-activated receptor 1 (PAR1). In order to better 
assess these factors, we obtained a novel detailed temporal and spatial profile of thrombin 
activity in a mouse model of permanent middle cerebral artery occlusion (pMCAo).
Methods: Thrombin activity was measured by fluorescence spectroscopy on coronal 
slices taken from the ipsilateral and contralateral hemispheres 2, 5, and 24 h following 
pMCAo (n = 5, 6, 5 mice, respectively). Its spatial distribution was determined by punch 
samples taken from the ischemic core and penumbra and further confirmed using 
an enzyme histochemistry technique (n =  4). Levels of PAR1 were determined using 
western blot.
results: Two hours following pMCAo, thrombin activity in the stroke core was already 
significantly higher than the contralateral area (11 ± 5 vs. 2 ± 1 mU/ml). At 5 and 24 h, 
thrombin activity continued to rise linearly (r = 0.998, p = 0.001) and to expand in the 
ischemic hemisphere beyond the ischemic core reaching deleterious levels of 271 ± 117 
and 123 ± 14 mU/ml (mean ± SEM) in the basal ganglia and ischemic cortex, respec-
tively. The peak elevation of thrombin activity in the ischemic core that was confirmed by 
fluorescence histochemistry was in good correlation with the infarcts areas. PAR1 levels 
in the ischemic core decreased as stroke progressed and thrombin activity increased.
conclusion: In conclusion, there is a time- and space-related increase in brain throm-
bin activity in acute ischemic stroke that is closely related to the progression of brain 
damage. These results may be useful in the development of therapeutic strategies for 
ischemic stroke that involve the thrombin-PAR1 pathway in order to prevent secondary 
thrombin related brain damage.
Keywords: ischemic stroke, thrombin, permanent middle cerebral artery occlusion, protease-activated receptor, 
endothelial protein c receptor
Abbreviations: BBB, blood–brain barrier; EPCR, endothelial cell protein C receptor; NSA, 5-nitrosalicylaldehyde; OGD, 
oxygen-glucose deprivation; PAR1, protease-activated receptor 1; pMCAo, permanent middle cerebral artery occlusion; PR3, 
proteinase 3; TTC, triphenyl tetrazolium chloride.
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inTrODUcTiOn
The “time is brain” paradigm is now well established in acute stroke 
care and emphasizes that neuronal tissue is rapidly lost as stroke 
progresses (1). Similarly, in permanent middle cerebral artery 
occlusion (pMCAo) performed in rats, infarction in the ischemic 
core progresses rapidly and the ischemic damage expands to the 
peripheral region with time (2). Understanding the mechanisms 
underlying the propagation of damage during stroke progression 
is critical for targeting effective treatments that can minimize 
irreversible neuronal damage.
Thrombin is a coagulation factor and a target for prevention of 
cardioembolic stroke (3, 4). In addition to its role in thrombogen-
esis, thrombin has important pleiotropic effects through the acti-
vation of its major receptor, protease-activated receptor 1 (PAR1) 
(5, 6). Activation of this receptor by low concentrations of throm-
bin may have neuroprotective effects, while at higher concentra-
tions thrombin has deleterious effects (7–11). In the setting of an 
acute ischemic stroke, high thrombin levels have been detected in 
the infarct area, possibly as a consequence of blood–brain barrier 
opening (12, 13) or as a result of its local synthesis in the brain 
(14, 15) or both. Functionally, thrombin has been shown to cause 
synaptic dysfunction (15–19) and later, on vascular disruption, 
inflammatory response and neuronal damage (20–22), through the 
activation of PAR1 (13, 20). Indeed, the toxic effects of thrombin in 
the central nervous system have been shown in various ischemia 
models where neuroprotection could be achieved by PAR1 dele-
tion (22). Recently, it was reported in pre-clinical studies that the 
direct thrombin inhibitor, argatroban, is protective when it is given 
immediately or after 1, 2, 3, but not 4 h delay from the ischemic 
event (23, 24). Moreover, there are clinical data that suggest that 
thrombin inhibition may be effective not only in prevention of car-
dioembolic stroke but also in the context of acute stroke (25–27). 
In addition, Chen et  al. showed that continuous administration 
of PAR1 antagonist immediately after MCA occlusion decreased 
the level of neurovascular injury (13). However, in studies of 
the PAR1 antagonist, Vorapaxar (Merck, USA), in patients with 
prior ischemic stroke, there was an increased risk of intracranial 
hemorrhage without an improvement in major vascular events 
(28). Thus, better understanding the role of thrombin and PAR1 
progression following ischemic event may have significant inputs 
for the development of therapeutic strategies based on thrombin-
PAR1 pathway.
Thrombin also cleaves the zymogen protein C (PC) to its 
activated form (aPC). Effective activation of PC by thrombin 
requires the transmembrane glycoprotein, thrombomodulin 
(TM), as a cofactor. PC activation by the thrombin–TM com-
plex is enhanced ~20-fold in  vivo when PC is bound to the 
endothelial cell protein C receptor (EPCR) (29). Retention of 
aPC bound to EPCR allows aPC to express multiple cytoprotec-
tive activities that involve PAR1. These cytoprotective activities 
include aPC-mediated anti-inflammatory and anti-apoptotic 
activities, alterations of gene expression profiles, and protection 
of endothelial barrier functions (30–33). Recently, we reported 
that different concentrations of thrombin affect long-term poten-
tiation (LTP) through different molecular routes converging on 
PAR1. High thrombin concentrations induce a slow onset LTP, 
whereas low concentrations of thrombin promote LTP through 
aPC–EPCR-mediated mechanism (18).
In order to examine the role of thrombin–PAR1–EPCR during 
stroke progression, we sought to determine the profiles in time 
and space of thrombin activity as well as the relevant PAR1 and 
EPCR levels in mice brains during pMCAo. Mapping thrombin 
activity throughout the brain provided the opportunity to assess 
both the ischemic core and its surrounding penumbral areas. This 
is of particular importance since the thrombin-PAR-1 pathway 
is an attractive target for the development of novel therapeutics 
for ischemic stroke (13, 19, 22, 23, 34–36) and may potentially 
prevent secondary thrombin-related brain damage. Clarifying 
the temporal and spatial profiles of thrombin and PAR1 follow-
ing an ischemic event is fundamental for determining therapeutic 
strategies based on this pathway.
MaTerials anD MeThODs
animals
Studies were carried out on 8-week-old male C57BL6 mice 
(23–30 gram, Harlan Laboratories Inc., Israel). Mice were kept at 
the animal house in mouse cages (six/cage) with free access to 
food and water with a 12/12-h light–dark circle. Anesthesia was 
performed with 2.5% isoflurane mixed in oxygen and delivered 
through a facemask. This type of anesthesia is common for this 
stroke model. PMCAo was performed using the common filament 
model based on our previously reported technique (12), using 
silicone-coated filament (Doccol Corp, Redlands, CA, USA). 
Mice were sacrificed using 100 µl pental by i.p. administration. 
Immediately prior to sacrifice, motor deficits were measured for 
each animal and scored using a 5-point Neurologic Severity Scores 
described as follows (37): 0, no neurologic deficit; 1, failure to 
extend left forepaw fully; 2, circling to the left; 3, falling to the 
left; 4, depressed level of consciousness and failure to walk sponta-
neously. Mice were divided into three groups according to the sac-
rifice time: 2 (n = 5), 5 (n = 6), and 24 (n = 5) h following pMCAo. 
Another group of healthy mice served as control (n = 5). Sample 
sizes were chosen based on the magnitude of thrombin changes 
in our previous experiences (12, 38). Exclusion criteria include 
massive bleeding during surgery and/or intracerebral hemorrhage.
Thrombin activity assay
Thrombin activity was measured using a fluorometric assay as 
described previously (12, 39). Briefly, thrombin activity was 
measured on fresh coronal slices taken from the ischemic and 
contralateral hemispheres by a fluorometric assay, quantifying 
the cleavage of the synthetic peptide substrate Boc-Asp(OBzl)- 
Pro-Arg-AMC (I-1560 Bachem, Switzerland). Following sacrifice, 
the brain of each animal was immediately removed and placed in 
a steel brain matrix (1 mm, Coronal; Stoelting; IL, USA). First, the 
brain was cut sagittally in its midline so the left contralateral and 
the right ischemic hemispheres were separated. Then, the brain 
was cut starting at its anterior side (starting at slice # 3, 2 mm 
anterior to the bregma), into coronal 1-mm thick slices. The slices 
were placed into black microplate (Nunc; Denmark) containing 
the substrate buffer. Measurements were performed microplate 
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reader (Tecan; infinite 200; Switzerland) with excitation and 
emission filters of 360 ± 35 and 460 ± 35 nm, respectively. For 
calibration, known concentrations of bovine thrombin (Sigma-
Aldrich, Israel) were used in the same assay.
Distribution of Thrombin activity levels  
in Mouse Brain following pMcao
The spatial distribution of thrombin activity in the ischemic 
core (coronal slice #6 as described in the previous section) was 
determined 24 h following pMCAo, using the thrombin activity 
assay and 1.5-mm diameter tissue punches that were taken from 
the cortical and basal ganglia areas in the ischemic and contralat-
eral hemisphere. Each tissue sample was placed in a separate 
well in the microplate, and thrombin activity was measured using 
the thrombin activity assay. Following removal of the punch tissue 
samples, the punctured slices were stained using triphenyltetra-
zolium chloride (TTC) for infarct assessment.
histochemical Visualization of Thrombin 
activity in Mouse Brain following pMcao
In addition to the tissue punches technique, the spatial distribu-
tion of thrombin activity in mice brain following pMCAo was 
determined using a novel enzyme histochemical method for visu-
alization of the thrombin activity location in brain slice that we 
have developed (38). Briefly, the method is based on the cleavage 
of the substrate, Boc-Asp(OBzl)-Pro-Arg-4MβNA by thrombin 
to liberate free 4MβNA which, in the presence of 5-nitrosalicyla-
ldehyde (NSA), is captured, yielding an insoluble yellow fluores-
cent product that marks the site of thrombin activity.
Twenty-four hours following pMCAo, mice were sacrificed 
and their brains were immediately removed and inserted into 30% 
sucrose solution for 24 h at 4°C. Thereafter, the brains were cut 
into 20 µm coronal slices using a cryostat (Leica CM1850, Leica, 
Germany), and the cut sections were picked up on microscopic 
glass slides (Superfrost Plus, Thermo Scientific, USA). For throm-
bin activity staining, the slices were incubated in a solution con-
taining 93 µl of thrombin buffer (50 mM TRIS/HCl, pH 7.0, 0.15 M 
NaCl, 1 mM CaCl2), 1 µl (0.6 mM) NSA, 1 µl of an aminopeptidase 
inhibitor bestatin (0.1 mg/ml, Cayman Chemical Company, USA) 
and 5 µl (0.1 mM) of the thrombin substrate Boc-Asp(OBzl)-Pro-
Arg-4MβNA (GL Biochem, Shanghai, China). The stained slices 
were placed at room temperature for 24 h. The specificity of the 
method for thrombin activity was verified using sections that were 
incubated in the histochemical solution containing 60 µM of the 
highly specific thrombin inhibitor, Nα-(2-naphthylsulfonylglycyl)-
4-amidino-(d,l)-phenylalanine piperidide acetate (NAPAP, Pefa-
bloc TH, Sigma-Aldrich, Israel). The reaction was terminated by 
rinsing the sections in cold 50 mM TRIS/HCL, pH 7.0. Next, the 
sections were fixed using 4% paraformaldehyde for 20 min, washed 
with PBS and 0.1% Triton X-100, and incubated for 10 min with 
Hoechst (1:1,000, hoe-33342, Sigma-Aldrich, Israel) for nuclear 
staining. Finally, the sections were air dried and closed with 
mounting media and cover glass. Thrombin activity localization 
and hoechst staining were visualized using inverted fluorescence 
microscope (I × 81, Olympus, Japan) with a filter cube U-MWU2 
(BP 300-385, BA420, DM400, Olympus, Japan).
Western Blot
Following the thrombin activity assay, coronal slices numbers 
5–7 from each hemisphere were pooled and homogenized using 
a pestle motor mixer (Argos Technologies, USA). Proteins from 
the brain homogenates were separated by polyacrylamide gel elec-
trophoresis and transferred onto nitrocellulose membranes for 
western blot analysis. Membranes were incubated with primary 
rabbit anti PAR1 antibody (1:500, ABCAM-ab32611, Abcam, 
USA) and primary rabbit anti EPCR antibody (1:500, NBP2-
21578, Novus, USA), followed by horseradish peroxidase-
conjugated goat anti-rabbit antibody (Jackson Immunoresearch 
Laboratories, USA). Protein signals were visualized using 
enhanced chemiluminescence assay kit (Thermo Scientific, USA). 
Bands intensities were quantified using Image J, a java-based 
image processing program.
statistics analysis
Statistical analyses was conducted using SPSS v. 22 for Windows 
(IBM, NY, USA). One or 2-way ANOVA followed by post hoc test 
was applied on normally distributed data set. For data which were 
not normally distributed, Wilcoxon signed-rank and Kruskal–
Wallis tests were used. Pearson and Spearman correlations were 
used for parametric and non-parametric variables. All numerical 
data are expressed as mean ± SEM, unless otherwise indicated. 
p-Values of <0.05 were considered significant.
resUlTs
Temporal and spatial Profile of Thrombin 
activity in Whole slices following pMcao
The pMCAo procedure in 11 mice resulted in consistent but 
moderate neurological deficits in all groups with a trend for more 
severe outcome in the 24 h group (median = 0, 2, 2, 3 for control 
mice and mice that underwent 2, 5, and 24 h pMCAo respectively; 
p =  0.001, by Kruskal–Wallis test). In order to determine the 
temporal profile of thrombin activity in mouse brain following 
a focal ischemic event, we measured brain thrombin activity 
levels 2, 5, and 24 h following pMCAo (Table S1 in Supplementary 
Material).
Figure  1 presents the mean thrombin activity levels in the 
ischemic and contralateral hemispheres at various time intervals 
after pMCAo. A repeated measures model was used to assess 
the association between slice number, occlusion time (control, 
2, 5, and 24 h), the interaction between the two, and thrombin 
activity. In the anterior and middle parts of the ischemic hemi-
sphere (slices 3–8 right), a significant effect was found for slice 
number [F(1.150, 4.598) = 76.584, p = 0.004] and occlusion time 
[F(1.726, 6.904) = 13.826, p = 0.0004] with a significant interac-
tion between the two [F(2.090, 8.360) = 7.271, p = 0.014]. In a 
post hoc analysis, the source of the difference between slice num-
bers was from the comparison of slices 3, 4, 5, 7, and 8 to slice 6 
(p = 0.002, p = 0.016, p = 0.067, p = 0.009, p = 0.015). In addition, 
the source of the difference between occlusion times was from 
the comparison of control with the stroke groups (p =  0.047; 
p = 0.041; p = 0.001 for 2, 5 and 24 h, respectively). These find-
ings reflect a substantial increase in thrombin activity at 24  h 
FigUre 1 | Thrombin activity in the ischemic hemisphere following 
permanent middle cerebral artery occlusion. Mean thrombin activity 
levels measured in brain slices taken from the right ischemic (a) and left 
contralateral (B) hemispheres, at the indicated time intervals after right 
permanent MCAo. Slices were numbered from anterior (#3) to posterior 
(#11), slices’ thickness = 1 mm. Inset is a plot of the mean thrombin activity 
levels that were measured in slice #6 as function of occlusion time.  
n represent number of mice that were used in each group.
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compared to 5 h post ischemia (p = 0.001), as clearly evident from 
Figure  1A. Strikingly, a linear correlation was found between 
thrombin activity levels that were measured in the ischemic core 
(slice #6) to occlusion time (r =  0.998, p =  0.001 by Pearson 
correlation; inset in Figure  1A). In contrast to the ischemic 
hemisphere, in the anterior and middle parts of the contralateral 
hemisphere (slices 3–8 left), although there was a moderate 
effect for slice number [F(1.888, 7.552) = 8.241, p = 0.013], no 
significant effect was found for occlusion time (p = 0.358) nor 
for the interaction between the two (p = 0.433, Figure 1B). At all 
time points, thrombin activity levels in the ischemic hemisphere 
were higher compared to the contralateral hemisphere {2  h 
[F(1.000, 4.000) = 21.908, p = 0.009]; 5 h [F(1.000, 5.000) = 4.934, 
p = 0.077]; 24 h [F(1.000, 4.000) = 42.096, p = 0.003]}. In the 
control group, no significant differences was found between the 
two hemispheres (p = 0.57). In the posterior part of the ischemic 
hemisphere (slices 9–11), thrombin activity was not significantly 
changed. No significant effect was found for either for slice 
number (p = 0.821) or for occlusion time (p = 0.278) in these 
posterior slices.
spatial Distribution of Thrombin activity  
in Brain slice
Since thrombin levels were maximally elevated 24  h following 
stroke induction, we further evaluated the spatial distribution 
of this activity by obtaining punch samples from mice (n =  4) 
which underwent pMCAo at this time point. The localization of 
the standard punch samples was from the core area of the ischemic 
damage in the basal ganglia and in the cortical area correspond-
ing to the penumbra (40–42). These areas (C,D, respectively) and 
corresponding areas in the contralateral hemisphere (A,B) are 
marked out in a representative slice stained for ischemic damage 
by TTC as presented in Figure 2A. The highest thrombin activity 
levels were measured in the basal ganglia of the ischemic hemi-
sphere, and they were higher compared to those measured in the 
ischemic cortex (271 ± 117 vs. 122 ± 27 mU/ml; n = 4; p = 0.072, 
by Wilcoxon signed-rank test; Figure  2B). As expected, these 
thrombin activity values that were measured in both the cortex 
and the basal ganglia of the ischemic hemisphere were higher 
compared to the corresponding areas in the contralateral slices 
(122 ± 27, 271 ± 117, vs. 3 ± 3, 10 ± 6 mU/ml; n = 4; p = 0.039 
and 0.039, respectively, by Wilcoxon signed-rank test; Figure 2B).
The distribution of thrombin activity in the core vs. sur-
rounding areas was further evaluated using a fluorescence 
histochemical method. Figures 2C–E are representative slides 
obtained from one animal out of five examined and presents 
the topographic distribution of thrombin activity 24 h follow-
ing pMCAo. High density of small, discrete, yellow-orange 
fluorescent needle shaped crystals that mark the locations 
of thrombin activity (Figure  2F) were observed in the right 
ischemic hemisphere in the cortical areas and in the basal 
ganglia compared to lower thrombin activity contralaterally 
(Figure  2C). The histochemical localization of thrombin 
activity corresponds to the infarct areas per TTC staining 
and to areas with high thrombin activity levels as determined 
using the thrombin activity assay and tissue punches tech-
nique (Figures  2A,B). Interestingly, higher thrombin activ-
ity levels were observed in the deep layers of the ischemic 
parietal cortex compared to lower thrombin activity in 
its upper layers (Figures 2C–E). No staining was seen in the 
corpus callosum of the ischemic hemisphere (Figures 2C–E) 
and in the sections that were incubated with the thrombin 
inhibitor NAPAP (Figure 2G).
Par1 and ePcr levels following pMcao
Figure  3 presents levels of PAR1 and EPCR in the ischemic 
hemispheres relative to the contralateral hemispheres measured 
by western blot technique at 2, 5, and 24 h following pMCAo. In 
parallel to the increase in thrombin activity in the ischemic hemi-
sphere, PAR1 levels decreased compared to the contralateral area 
upon MCAo. Following 5 h of pMCAo, the ratio of PAR1 levels 
in the ischemic core to contralateral areas was lower compared 
to control mice (Figure 3A, p = 0.055, by Kruskal–Wallis test). 
This decrease was further augmented following 24 h of pMCAo 
(p = 0.004; Figure 3A). There was a significant inverse correla-
tion between thrombin activity and PAR1 level as can be seen 
in Figure 4 (r = −0.491, p = 0.037). Similarly, the ratio of EPCR 
FigUre 2 | spatial distribution of thrombin activity in brain slice. (a) The locations of the 1.5-mm diameter tissue punches sampled from fresh slices  
(slice location 1 mm posterior to the bregma; slice #6 in Figure 1). Typical triphenyltetrazolium chloride staining of the relevant slice used in these analyses is 
presented (representative of four slices developed by this method). Infarct regions are colored by white and intact brain regions by red. (B) Mean thrombin activity 
levels (milliunits per milliliter of tissue ± SEM) and its data distribution that were measured at the cortex and basal ganglia in the ischemic and contralateral 
hemispheres following permanent middle cerebral artery occlusion (pMCAo). (c–e) Fluorescence photomicrograph of coronal sections of mice brains 24 h following 
pMCAo that were incubated with Boc-Asp(OBzl)-Pro-Arg-4MβNA. A mosaic was formed by merging 20 pictures, each picture magnification 40× (c). The small, 
discrete, yellow-orange fluorescent, needle shaped crystals represent the locations of thrombin activity. Cell nuclei were stained by hoechst and appear as blue 
spots (c,D). (F) Higher-power photomicrograph of the typical appearance and distribution of the thrombin activity reaction product in the cortical, basal ganglia 
areas in the ischemic hemispheres (magnification 200×). (g) Absence of thrombin activity reaction product in tissue incubated in histochemical staining solution 
containing the specific thrombin inhibitor NAPAP. A mosaic was formed by merging 20 pictures, each picture magnification 40×.
FigUre 3 | Protease-activated receptor 1 (Par1) and endothelial cell protein c receptor (ePcr) levels decrease following permanent middle 
cerebral artery occlusion (pMcao). Ratio of PAR1 (a) and EPCR (B) levels in the ischemic core vs. their levels in corresponding areas in the contralateral 
hemisphere, as measured at various times intervals after right pMCAo (*p = 0.055, **p = 0.004, by Kruskal–Wallis test, n = 5; ***p = 0.047, by one-way ANOVA 
following post hoc Tukey’s test, n = 4;). Is = Ischemic; Co = contralateral.
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FigUre 4 | negative correlation between thrombin activity and 
protease-activated receptor 1 (Par1) levels. Ratio of PAR1 levels in  
the ischemic core vs. the corresponding areas in the contralateral hemisphere 
as a function of the mean thrombin activity measured in the ischemic core 
(slices # 5, 6, 7) 2, 5, and 24 h, following permanent middle cerebral artery 
occlusion. The correlation was significant by Spearman’s test (r = −0.491, 
p = 0.037).
6
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were measured in the ischemic core 5 h following MCAo were 
below the deleterious limit of 60  mU/ml. Interestingly, this 
time frame fits the therapeutic window for effective reperfusion 
therapy (43).
In the current study, thrombin activity levels that were measured 
in the ischemic core 24 h following pMCAo were higher com-
pared to those measured in a previous study of ours (12). The 
reason for these differences is probably due to the different types 
of filament that were used to occlude the MCA in each study 
(commercial silicone-coated filament 4-mm length compared to 
heat-blunted 6–0 suture coated with poly-l-lysine). Indeed, Guan 
et al. showed in a MCAo model performed in rats, positive cor-
relation between suture coating length and infarct volume (44). 
Likewise, our group has found a positive correlation between 
infarcts volume to thrombin activity levels (12, 39). Not surpris-
ingly, thrombin activity levels that were measured in the ischemic 
core 24 h following 90 min tMCAo (39) were lower compared to 
those measured following pMCAo. It is expected that in the tran-
sient model, most of the blood vessels will undergo reperfusion 
in such a situation and that there will be less thrombin activity 
left over from the initial tissue damage as well as less propagation 
of thrombin activity due to tissue ischemia and continued occlu-
sion of blood vessels. In contrast to our previous study (39), in 
this study, we present mapping of brain thrombin activity levels 
following pMCAo, at several time points from the ischemic event 
and not just 24 h later.
The specific time points that we used in this study represent 
critical stages in the progression of stroke: 2  h—acute stage, 
immediately after the onset; 5  h—the end of the therapeutic 
window; 24 h—peak point of thrombin activity following global 
ischemia (45) and optimal time point for TTC staining. The tem-
poral profile of thrombin activity that is presented in this study 
is comparable to that found following global cerebral ischemia 
that was performed using bilateral common carotid artery occlu-
sion (BCCAO) (45). Following BCCAO, brain thrombin activity 
slightly increased at 4 h, peaked at 24 h, and declined at 72 h. The 
rapid increase of thrombin activity in the first hours is compat-
ible with the findings that thrombin activity positively correlates 
to infarct volume (12, 39) and to the very early appearance of 
ischemic lesion that was observed following pMCAo (2).
The highest thrombin activity levels measured biochemically 
in tissue punches were found in infarct areas based on TTC stain-
ing. This finding is in agreement with our previous finding of a 
positive correlation between thrombin activity level and infarct size 
(12, 39). Furthermore, we have found that the distribution of 
thrombin activity in the tested slices was similar in both the punch 
method and the new higher resolution histochemical method. In 
both methods, high thrombin activity levels were observed in the 
right ischemic hemisphere in the cortical areas and in the basal 
ganglia compared to negligible thrombin activity levels contralat-
erally. Interestingly, non-homogeneous distribution of thrombin 
activity was observed in the cortical layers of the ischemic hemi-
sphere with higher activity in the deep layers. Furthermore, no 
staining of thrombin activity was seen in the corpus callosum of 
the ischemic hemisphere. Further experiments are needed in order 
to better clarify these spatial patterns.
levels in the ischemic core to the contralateral areas decreased 
with time after pMCAo, and this was lower compared to control 
mice 24  h following pMCAo (p =  0.047 by one-way ANOVA 
following post hoc Tukey’s test; Figure 3B).
DiscUssiOn
In the present study, we found that thrombin activity in the 
ischemic core started to rise 2 h after MCAo, and activity lev-
els continued to rise and to expand into additional areas that 
surround the ischemic core. Twenty-four hours after MCAo, 
levels of thrombin activity rose dramatically in the anterior and 
middle regions of the ischemic hemisphere reaching peak levels 
in the ischemic core. Strikingly, thrombin activity levels in the 
ischemic core rose linearly over time. In contrast, thrombin activity 
in slices that were taken from areas that are supplied by the pos-
terior circulation (#9–11), and in the contralateral hemisphere 
remained as expected unchanged. Levels of thrombin activity 
that were measured using discrete tissue samples taken from 
the ischemic core reached values that are more than two times 
higher compared to those obtained when sampling the entire 
hemisphere. It is likely that the levels found when sampling 
the entire hemisphere are an underestimation and represent an 
average between higher levels in the infarct core and lower levels 
in perinfarct areas. The propagation of the thrombin activity 
across slices suggests a time-dependent expansion of the core 
of thrombin activity.
Previously, we reported that thrombin concentrations above 
60  mU/ml are able to alter synaptic responses by increasing 
paired pulse facilitation as well as network excitability leading to 
synaptic dysfunction (39). In this study, we found a linear increase 
of thrombin activity and that 24 h following occlusion, thrombin 
activity in the ischemic hemisphere is considerably above the 
deleterious threshold. In contrast, thrombin activity levels that 
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In parallel with the linear increase of thrombin activity, 
PAR1 levels in the ischemic core decreased as stroke progressed. 
These results are in agreement with the study of Chen et al. that 
found decrease in PAR1 levels in rat brains in the first hours 
after tMCAo (13). In contrast, PAR1 levels were raised in rat 
hippocampal slice cultures that were subject to experimental 
ischemia [oxygen-glucose deprivation (OGD)] (46) and in mice 
brains undergoing global cerebral ischemia (45). A possible 
explanation for this apparent conflict is that in the MCAo model, 
high level of thrombin activity that originates in the blood stream 
(13), enters into the brain tissue through vascular disruption, 
and activates PAR1 on cell membranes. Consequently, PAR1 rap-
idly internalize and degrade. The negative correlation observed 
between thrombin activity in the ischemic core to the ratio of 
PAR1 levels in the ischemic core vs. the contralateral hemisphere 
emphasizes the link between PAR1 reduction and elevated 
thrombin activity. In contrast, in brain slices that are subjected 
to ischemic conditions such as OGD, no circulating coagulation 
factors are involved and the time points examined were some-
what shorter. Thrombin that is generated in the brain cells rises 
(14, 15) and as a result PAR1, its own receptor, may first increase 
as a complementary step, but these receptors are then cleaved 
and internalized leading to reduced levels. It is hypothesized 
that inhibiting the levels of thrombin during acute stroke will 
normalize PAR1 levels at the 2–24 hour time frame.
Several studies have demonstrated the neuroprotective effects 
of deletion, inhibition or silencing PAR1 in brain ischemia (13, 20, 
47–49). In a previous study we have shown that pharmacological 
inhibition of either thrombin or PAR1, restores physiological 
synaptic plasticity that was blocked in OGD neuronal networks. 
Moreover, we have found that hippocampal slices prepared from 
PAR1-KO mice that were exposed to OGD have normal synaptic 
transmission (15). In the current study we found that PAR1 levels 
in the ischemic core start to decrease 5 h following MCAo, as a 
results it is likely that treatment using PAR1 inhibitors might be 
effective only if administered in the first hours from the ischemic 
event.
Endothelial cell protein C receptor decreased in the ischemic 
core only at a late phase, 24  h following pMCAo. Proteinase 3 
(PR3) a neutrophil granule proteinase is elevated in the brain fol-
lowing stroke and is involved in the inflammatory process (50). 
Villegas-Mendez et al found high affinity interaction between the 
neutrophil protease PR3, and the EPCR, which results in the pro-
teolytic degradation of the receptor (51). Degradation of EPCR 
with consequent loss of aPC generation is likely to contribute 
to the already known proinflammatory roles of PR3 (51).
The novelty of the present study is to show for the first time 
quantitative characterization of the temporal and spatial profiles 
of brain thrombin activity during the course of acute ischemic 
stroke. The results reveals continuous increase and spatial expan-
sion of thrombin activity in mice brains following MCAo even in 
areas outside the ischemic core. Furthermore, changes in PAR1 
and EPCR levels during stroke progress are presented. The poten-
tial translation of these results into the clinic is by consideration 
of pharmacologically inhibiting thrombin activity in the brain 
early after an acute ischemic event as an optional complementary 
therapy for acute stroke in order to prevent secondary thrombin 
related brain damage. However, due to the continuous increase of 
thrombin activity, the therapeutic dose of the thrombin inhibitor 
should be time dependent. In contrast to thrombin activity, the 
decrease of PAR1 during stroke progress suggests that PAR1 
inhibition might be not affective if it will be given in time delay 
from the ischemic event.
The main limitation of this study is that the experiments were 
performed only on healthy young male mice. In order to translate 
the results of this study to clinical implementation, future studies 
should include old as well as female mice. In addition, in future 
experiments, it will be interesting to study the role of thrombin 
activity in the transient occlusion model that simulates reperfu-
sion of the artery.
In summary, findings of this study underscore the temporal 
and spatial profile of brain thrombin activity during the course of 
acute ischemic stroke. The dramatic increase over time in brain 
thrombin activity is in agreement with the therapeutic window 
for reperfusion therapy and the known progression of brain dam-
age and may constitute a potential complimentary target for acute 
ischemic stroke therapy.
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